This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Zimmer Biomet (ZBH) in Q2 Earnings?
by Zacks Equity Research
Focusing on the thrust areas like quality correction, supply recovery efforts and product introductions, Zimmer Biomet (ZBH) is expected to retain robust top-line numbers within its S.E.T. arm.
Zimmer Biomet (ZBH) Down 2.9% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Zimmer Biomet (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zimmer Biomet New System Gets FDA Nod, to Boost Spine Wing
by Zacks Equity Research
Zimmer Biomet (ZBH) receives FDA's approval for the new system, which is likely to augment the company's lumbar spacers portfolio.
Generac, Maximus, Norbord, Boeing and Zimmer Biomet as Zacks Bull and Bear of the Day
by Zacks Equity Research
Generac, Maximus, Norbord, Boeing and Zimmer Biomet as Zacks Bull and Bear of the Day
3 Stocks Back In Play After U.S.-China Trade War Stalls
by Taye Baldinazzo
On Sunday, the U.S. and China put trade tensions aside in hopes of reaching a stable and broad trade agreement. With previously at-risk stocks beginning to rise, there seems to be room for profit in these formerly questionable markets. Read on for three stocks that investors should reconsider as the trade war is put on hold.
Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
Zimmer Biomet (ZBH) issues full-year 2018 sales and earnings guidance in Q1.
Zimmer Biomet (ZBH) Beats on Q1 Earnings & Revenue Estimates
by Zacks Equity Research
Zimmer Biomet (ZBH) rides on strength in Knee, Hip and S.E.T. segments in Q1.
Can S.E.T. Aid Zimmer (ZBH) Q1 Earnings Despite Supply Woes?
by Zacks Equity Research
Several FDA clearances within S.E.T since last November raise hope for Zimmer Biomet (ZBH) in Q1.
Supply Delay Hits Zimmer Biomet, Operational Plan Buoys Hope
by Zacks Equity Research
Zimmer Biomet's (ZBH) dull Knee sales continue to bother due to slower pace of supply recovery and sales recapture of certain key brands.
Trade War Fears Grip MedTech: 3 Stocks on the Line of Fire
by Urmimala Biswas
Chances of a retaliation from China leads to widespread losses in the medical device sector.
New Strong Sell Stocks for February 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Zimmer Biomet (ZBH) Q4 Earnings Meet, Sales Miss Estimates
by Zacks Equity Research
Zimmer Biomet (ZBH) rides high on all segments.
Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q4 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q4.
Zimmer Biomet Strong on Positive Data From PROGRESS II Study
by Zacks Equity Research
Zimmer Biomet (ZBH) consistently endeavors to improve its knee business.
Zimmer Biomet (ZBH) Surges: Stock Moves 6.1% Higher
by Zacks Equity Research
Zimmer Biomet (ZBH) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.
New Strong Sell Stocks for December 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Zimmer Biomet Hurt by Supply Delay, Knee Challenges Remain
by Zacks Equity Research
Zimmer Biomet (ZBH) struggles with supply delay problem related to some of its products, causing inability to win back lost customers and gain new ones.
New Strong Sell Stocks for November 20th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Zimmer Biomet (ZBH) Misses Q3 Earnings, Meets Sales Estimate
by Zacks Equity Research
Zimmer Biomet (ZBH) posts in line revenues on the back of soft Knees and Hips segments in Q3.
5 Earnings All-Stars to Start the Week
by Tracey Ryniec
With over 1,000 companies reporting, these are some of the best earnings charts to start the week.
Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q3 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q3.
Is Zimmer Biomet (ZBH) a Great Stock for Value Investors?
by Zacks Equity Research
Is Zimmer Biomet (ZBH) a great pick from the value investor's perspective right now? Read on to know more.
Zimmer Biomet (ZBH) Launches Persona Partial Knee System
by Zacks Equity Research
Zimmer Biomet (ZBH) is constantly trying to turn its Knees business around. Keeping in line with the efforts, the company has launched Persona Partial Knee System.
New Strong Sell Stocks for September 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Zimmer (ZBH) Plagued by Various Internal and External Issues
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to suffer a bad patch, entangled with issues including its decade-old CEO's recent exit post a dull earnings season due to poor knee business.